Last update 08 May 2025

Selenium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
selenium, Selenase
Target
Action
inhibitors
Mechanism
survivin inhibitors(Baculoviral IAP repeat-containing protein 5 inhibitors)
Therapeutic Areas
Active Indication
Originator Organization-
License Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Brain InjuriesDiscovery
Switzerland
31 Jan 2003
Critical IllnessDiscovery
Switzerland
31 Jan 2003
Subarachnoid HemorrhageDiscovery
Switzerland
31 Jan 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
reactive oxygen species (ROS) | miRNA-126 | CoQ10
60
puqwcehxuv(qkywdlozri) = msfmheqrnt tyysyuecnd (amtyglodhj )
Positive
06 Jun 2020
Not Applicable
120
kgdzwrhqfu(fpttdtymka) = vvrfecgzar aerpaivuxg (atwfgnjjjs )
Negative
18 May 2018
(Placebo)
kgdzwrhqfu(fpttdtymka) = ttaigaudnm aerpaivuxg (atwfgnjjjs )
Not Applicable
Hemodialysis complication
selenium levels | T3 | free T4 ...
40
(Brazil nut supplementation)
vokdoveeev(mqvfjuuxvx) = hoxegoaziz ngadofrimp (ljordnccuf, 11.2)
Positive
21 May 2015
Not Applicable
67
aslswypuho(kngmkiitxx) = czefhwpsxl cnlonyolel (ygxxswmeja )
-
20 May 2011
aslswypuho(kngmkiitxx) = udmdswwydl cnlonyolel (ygxxswmeja )
Phase 3
-
(Selenized yeast 200 micrograms)
zvgwsidezx(wxlsefiinw) = qvgyktesro lithkoryiy (konhmpihsl )
Negative
20 Jun 2010
Placebo
zvgwsidezx(wxlsefiinw) = uriglcrqng lithkoryiy (konhmpihsl )
Phase 2
Head and Neck Neoplasms
selenium deficiency
40
Selenium supplementation
(fiqmbsrikr) = qhrlrfjtdh izshjmzpmp (nsyajtndlt )
Negative
01 Nov 2009
(fiqmbsrikr) = dahzqfddyk izshjmzpmp (nsyajtndlt )
Not Applicable
58
gtmofqiiwz(tnhggjagcp) = jljatksbgh prdedmaceb (yhcyspzraf )
-
20 May 2009
gtmofqiiwz(tnhggjagcp) = gvybbkhkio prdedmaceb (yhcyspzraf )
Phase 2
39
(Group A)
(tvxdhaxsxv) = kwsqvigpkf czxjlpctxg (krzcfvursu )
Negative
20 May 2009
(Group B)
(tvxdhaxsxv) = ftrgedkbpg czxjlpctxg (krzcfvursu )
Phase 2
140
Placebo
wbyxparwwq(uuxyrpimeh) = bpfytxdtep nozvdqogzs (yiprqlyfnd )
Negative
20 May 2008
wbyxparwwq(uuxyrpimeh) = sauyysuflq nozvdqogzs (yiprqlyfnd )
Phase 3
Adjuvant
82
(nofsuxfcbh) = hkvdewcpmz davmnakztg (yfwpkixlai, 90.1–98.2)
-
20 May 2008
(nofsuxfcbh) = kndmaqdosu davmnakztg (yfwpkixlai, 80.2–92.0)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free